Related Experiment Video

Updated: Apr 23, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K

Tpl2 induces castration resistant prostate cancer progression and metastasis

Hye Won Lee1, Hyun Jung Cho, Se Jeong Lee

  • 1Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

International Journal of Cancer
|October 3, 2014
PubMed

Insights

Tumor progression locus 2 (Tpl2) kinase drives castration-resistant prostate cancer (CRPC) metastasis by activating key signaling pathways. Targeting Tpl2 offers a potential therapeutic strategy for advanced prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Metastatic castration-resistant prostate cancer (CRPC) represents the lethal progression of prostate cancer (PC).
  • Identifying key molecular drivers of CRPC metastasis is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of tumor progression locus 2 (Tpl2) kinase in the progression and metastasis of CRPC.
  • To elucidate the molecular mechanisms by which Tpl2 promotes CRPC.

Main Methods:

  • In vitro assays assessing proliferation, clonogenicity, migration, invasion, and chemoresistance of androgen depletion-independent (ADI) PC cells.
  • In vivo studies evaluating the impact of Tpl2 modulation on tumorigenic and metastatic potential.
  • Analysis of clinical PC databases to validate prognostic effects and molecular correlations.

Main Results:

  • Tpl2 kinase was identified as a fundamental driver of CRPC progression and metastasis.
  • Tpl2 upregulates CXCR4 and focal adhesion kinase (FAK), activating CXCL12/CXCR4 and FAK/Akt pathways.
  • Tpl2 kinase activity induces epithelial-mesenchymal transition (EMT) and stemness in ADI PC cells, enhancing their malignant potential.
  • Tpl2 overexpression/downregulation significantly impacted tumorigenesis and metastasis in vivo.
  • Clinical data confirmed the prognostic significance of Tpl2 and its correlation with EMT markers and CXCR4.

Conclusions:

  • Tpl2 kinase plays a critical role in promoting the metastatic progression of CRPC.
  • Tpl2's ability to induce EMT and stemness, alongside activating specific signaling pathways, underscores its importance in CRPC.
  • Tpl2 represents a promising novel therapeutic target for metastatic CRPC.
Keywords:
castration resistancemetastasisprostate cancertumor progression locus 2

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.3K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
684
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K